Jade Biosciences, Inc.
For the period ended Mar 31, 2025. Filed Apr 25, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed Apr 25, 2025
JBIO$16.40+5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| · · Three months ended March 31, · · | ||||||||
| · 2025 · 2024 · | ||||||||
| Cash flow from operating activities: · · · | ||||||||
| Net loss | | $(2,518) | | $(23,186) | | | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||||
| Stock-based compensation expense | | 1,185 | | 4,200 | | | ||
| Depreciation and amortization expense | | 4 | | 28 | | | ||
| Accretion of discounts and amortization of premiums on investments, net | | (225) | | (759) | | | ||
| Changes in operating assets and liabilities: | | | | | ||||
| Prepaid expenses and other current assets | | 331 | | (2,112) | | | ||
| Other long-term assets | | — | | 2 | | | ||
| Accounts payable | | (155) | | 835 | | | ||
| Accrued and other liabilities | | (1,151) | | (3,061) | | | ||
| Operating lease assets and liabilities, net | | (54) | | (12) | | | ||
| Other liabilities | | 202 | | 392 | | | ||
| Net cash used in operating activities | | $(2,381) | | $(23,673) | | | ||
| | | | | | | | | |
| Cash flow from investing activities: | | | | | ||||
| Purchases of short-term investments | | | — | | | (14,750) | | |
| Maturities of short-term investments | | | 12,850 | | | 23,583 | | |
| Net cash provided by investing activities | | $12,850 | | $8,833 | | | ||
| | | | | | | | | |
| Cash flow from financing activities: | | | | | ||||
| Payments for offering costs | | | — | | | (233) | | |
| Proceeds from issuance of common stock upon exercise of stock options | | — | | 704 | | | ||
| Net cash provided by financing activities | | $— | | $471 | | | ||
| | | | | | | | | |
| Net increase in cash and cash equivalents | | 10,469 | | (14,369) | | | ||
| Cash and cash equivalents at the beginning of the year | | 33,751 | | 23,491 | | | ||
| Cash and cash equivalents at the end of the period | | $44,220 | | $9,122 | | | ||
| | | | | | | | | |
| Supplemental disclosure of noncash investing and financing activities: | | | | | ||||
| Right-of-use asset obtained in exchange for operating lease liability | | $— | | $206 | | | ||
| Deferred offering costs included in accounts payable | | $— | | $82 | | | ||
AEROVATE THERAPEUTICS, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.